RaySearch Laboratories AB Class B ( (RSLBF) ) has released its Q4 earnings. Here is a breakdown of the information RaySearch Laboratories AB Class B presented to its investors.
RaySearch Laboratories AB, a medical technology company based in Sweden, specializes in developing innovative software solutions for cancer treatment, including its flagship products RayStation and RayCare, which are used in oncology centers worldwide. In its year-end report for 2024, RaySearch Laboratories AB reported an 8 percent increase in net sales for the fourth quarter, with a total net sales amounting to SEK 1,192.0 million for the full year, marking the highest in the company’s history. The operating profit for the year also saw a significant rise, reaching SEK 260.5 million compared to SEK 114.9 million in the previous year. Key highlights of the financial year include a substantial increase in license and support revenues, alongside strategic orders such as the purchase by GenesisCare UK and the clinical use of RayStation for proton arc therapy in Italy. Moreover, the company launched new product areas, including DrugLog and a liver ablation module, which further enhance its comprehensive suite of cancer treatment solutions. Looking ahead, RaySearch management remains optimistic, targeting an operating margin of at least 25 percent by 2026, backed by a strong financial position and ongoing advancements in cancer care innovation.